In a retrospective analysis of patients with unresectable melanoma, higher pretreatment tissue densities of CD16+ macrophages were associated with clinical benefit from combined CTLA-4 and PD-1 blockade. With further validation, this biomarker could serve as a tool in selecting between immune checkpoint inhibitor regimens. See related article by Lee et al., p. 2513.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330271 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-23-0490 | DOI Listing |
Publication Analysis
Top Keywords
cd16+ macrophages
8
combined ctla-4
8
ctla-4 pd-1
8
pd-1 blockade
8
macrophages emerging
4
emerging biomarker
4
biomarker combined
4
blockade retrospective
4
retrospective analysis
4
analysis patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!